WALTHAM, Mass., April 25, 2018 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:
SNDX), a clinical stage biopharmaceutical company developing an
innovative pipeline of cancer therapies, today announced five
poster presentations at the upcoming American Society of Clinical
Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago, Illinois.
Presentation Details
Title: ADVL1513: Results of a phase 1 trial of
entinostat, an oral histone deacetylase inhibitor, in pediatric
patients with recurrent or refractory solid tumors
First Author: Suman Malempati,
MD, Oregon Health and Science University
Abstract Number: 10556
Poster Session: Pediatric Oncology
Poster Board: 229
Date and Time: Saturday, June 2,
2018, 8:00-11:30 AM CT, Hall
A
Title: ENCORE 601: A phase 2 study of entinostat in
combination with pembrolizumab in patients with microsatellite
stable metastatic colorectal cancer
First Author: Nilofer Saba
Azad, MD, Sidney Kimmel Cancer Center at Johns Hopkins University
Abstract Number: 3557
Poster Session: Gastrointestinal (Colorectal) Cancer
Poster Board: 50
Date and Time: Sunday, June 3,
2018, 8:00-11:30 AM CT, Hall
A
Title: Efficacy and safety of entinostat (ENT) and
pembrolizumab (PEMBRO) in patients with non-small cell lung cancer
(NSCLC) previously treated with anti-PD-(L)1 therapy
First Author: Leena Gandhi,
MD, PhD, NYU Perlmutter Cancer Center
Abstract Number: 9036
Poster Session: Lung Cancer—Non-Small Cell Metastatic
Poster Board: 359
Date and Time: Sunday, June 3,
2018, 8:00-11:30 AM CT, Hall
A
Title: Entinostat in combination with nivolumab for
patients with advanced cholangiocarcinoma and pancreatic
adenocarcinoma
First Author: Marina Baretti,
MD, Sidney Kimmel Cancer Center at Johns
Hopkins University
Abstract Number: TPS4151
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Poster Board: 330a
Date and Time: Sunday, June 3,
2018, 8:00-11:30 AM CT, Hall
A
Title: Efficacy and safety of entinostat (ENT) and
pembrolizumab (PEMBRO) in patients with melanoma progressing on or
after a PD-1/L1 blocking antibody
First Author: Sanjiv S.
Agarwala, MD, St. Luke's Hospital
Abstract Number: 9530
Poster Session: Melanoma/Skin Cancers
Poster Board: 357
Date and Time: Monday, June 4,
2018, 1:15-4:45 PM CT, Hall
A
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies. The
Company is developing its lead product candidate, entinostat, a
once-weekly, oral, small molecule, class I HDAC inhibitor, in
combination with exemestane and several approved PD-1/PD-L1
antagonists. The Company's pipeline also includes SNDX-6352, a
monoclonal antibody that blocks the colony stimulating factor 1
(CSF-1) receptor, as well as a portfolio of potent and selective
inhibitors targeting the binding interaction of Menin with MLLr.
For more information, please visit www.syndax.com or follow
the Company on Twitter and LinkedIn.
Syndax's Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend," "believe" and similar expressions (as well as
other words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Syndax's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. Forward-looking statements contained in this press
release include, but are not limited to, statements about the
progress, timing, clinical development and scope of clinical trials
and the reporting of clinical data for Syndax's product candidates,
and the potential use of our product candidates to treat various
cancer indications. Many factors may cause differences between
current expectations and actual results including unexpected safety
or efficacy data observed during preclinical or clinical studies,
clinical trial site activation or enrollment rates that are lower
than expected, changes in expected or existing competition, changes
in the regulatory environment, failure of Syndax's collaborators to
support or advance collaborations or product candidates and
unexpected litigation or other disputes. Other factors that may
cause Syndax's actual results to differ from those expressed or
implied in the forward-looking statements in this press release are
discussed in Syndax's filings with the U.S. Securities and Exchange
Commission, including the "Risk Factors" sections contained
therein. Except as required by law, Syndax assumes no obligation to
update any forward-looking statements contained herein to reflect
any change in expectations, even as new information becomes
available.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
Tel 212.600.1902
SNDX-G
View original
content:http://www.prnewswire.com/news-releases/syndax-pharmaceuticals-announces-presentations-at-the-2018-american-society-of-clinical-oncology-annual-meeting-300636649.html
SOURCE Syndax Pharmaceuticals